Efficacy and safety of ixekizumab over 4 years of open-label treatment in a Phase 2 study in chronic plaque psoriasis

Authors
Category Primary study
ConferenceJournal of the European Academy of Dermatology and Venereology
Year 2016
This article has no abstract
Epistemonikos ID: 1d611f6f1692bbe8550c00c871e49bf4ec08eee1
First added on: Apr 29, 2026